The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated as part of its first-in-human tests.

In a departure from most deals, startup insitro will in-license Lilly’s delivery technology for its investigational liver-targeted siRNA therapies. The pharma will be eligible for milestones and royalties down the line.

Rona Therapeutics has secured $35m in its Series A+ financing round to advance its metabolic small interfering RNA (siRNA) pipeline in clinical settings.

Pharma giant AstraZeneca and UK biotech Aptamer Group are hoping to bolster the efficacy of small interfacing RNA (siRNA) therapies, using Aptamer’s Optimer delivery system.

The companies did not disclose the financials behind the collaboration but following the 3 July announcement, Aptamer’s shares were up by 18% to $0.95 (£0.74).

Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda.

Researchers are pitching a new vaccine method for infants that offers continued protection with just a single dose, even if the virus mutates, according to a new study that could set the stage for “universal vaccines.”

Boehringer Ingelheim is having another crack at using RNA to treat nonalcoholic steatohepatitis (NASH). Six years after inking deals for a pair of prospects, the German drugmaker has committed more than $2 billion in biobucks to enter into a multi-target pact with a Chinese biotech and its Swedish subsidiary.

A first-in-human trial of Eli Lilly’s experimental RNA interference drug lepodisiran has shown that just one dose reduced lipoprotein(a) – a risk factor for cardiovascular disease – by up to 94%, with reductions lasting almost a year.

Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).